Prime Medicine (PRME) Interest & Investment Income (2023 - 2026)
Prime Medicine's (PRME) quarterly Interest & Investment Income came in at $1.0 million in Q1 2026, down 13.62% YoY from $1.2 million in Q1 2025, and down 5.72% on a QoQ basis from $1.1 million in Q4 2025.
Prime Medicine (PRME) Interest & Investment Income (2023 - 2026) Analysis & Trends
Prime Medicine (PRME) has 4 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Interest & Investment Income fell 13.62% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 0.99% YoY) and the FY2025 annual result came in at $4.1 million, up 17.8% from the prior year.
- Interest & Investment Income declined to $1.0 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.5 million in Q4 2024 to a low of $410000.0 in Q3 2023.
- A 4-year average of $852333.3 and a median of $720000.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income surged 213.24% — and 2025, when it declined 29.58%.
- Tracing PRME's Interest & Investment Income over 4 years: stood at $491000.0 in 2023, then surged by 213.24% to $1.5 million in 2024, then decreased by 29.58% to $1.1 million in 2025, then fell by 5.72% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 788,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 788,000.00 |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 743,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 697,000.00 |
| Jun 30, 2024 | 611,000.00 |
| Mar 31, 2024 | 676,000.00 |
| Dec 31, 2023 | 491,000.00 |
| Sep 30, 2023 | 410,000.00 |
| Jun 30, 2023 | 635,000.00 |